The fatty acid synthesis pathway is a checkpoint for lipoteichoic acid synthesis in Staphylococcus aureus

This study reveals that in *Staphylococcus aureus*, the fatty acid synthesis (FASII) pathway acts as a critical checkpoint for lipoteichoic acid production by regulating intracellular glycerophosphate availability, thereby determining whether phosphatidylglycerol flux is directed toward essential LTA synthesis or alternative non-glycerophosphate lipids.

The Gist

The Big Picture: A Bacterial Factory in Crisis

Imagine Staphylococcus aureus (a common bacteria that can cause infections) as a busy factory. This factory has two main jobs:

1. Building the Walls: It constructs a tough outer shell to protect itself.
2. Making the "Velcro": It produces a sticky, brush-like substance called Lipoteichoic Acid (LTA) that sticks to the outside of the wall. This "Velcro" is crucial for the bacteria to divide, stay strong, and fight off our immune system.

The factory needs a specific raw material called Glycerol-3-Phosphate (GroP) to make this Velcro. However, the factory has a problem: it has to choose between using GroP to make the Velcro (LTA) or using it for other, less critical tasks.

The Discovery: The "Power Plant" Controls the "Velcro"

The scientists in this study discovered that the factory's ability to make Velcro depends entirely on its internal power plant, called FASII (Fatty Acid Synthesis).

Normally, the factory runs its own power plant to generate energy and materials. But, if you attack the factory with a specific antibiotic that shuts down this power plant, the bacteria doesn't die immediately. Instead, it has a clever backup plan: it grabs fuel from the outside environment (like a car switching from a gas engine to an electric battery).

The Twist: When the bacteria switches to this "external fuel" mode (bypassing its own power plant), something strange happens. Even though the factory is still running and growing, it stops making the Velcro (LTA).

The Investigation: Why Did the Velcro Disappear?

The researchers asked: Why does turning off the internal power plant stop the Velcro production?

They tested a few theories:

• Theory 1: Is the factory running out of money (ATP)?
  • Result: No. In fact, using external fuel actually saved the factory money. So, lack of energy wasn't the problem.
• Theory 2: Did the factory switch to bad building materials (Fatty Acids)?
  • Result: No. The researchers forced the bacteria to use the exact same building materials in both scenarios. The Velcro still disappeared when the internal power plant was turned off.
• Theory 3: Did the factory run out of the specific glue (GroP)?
  • Result: Bingo! When the internal power plant was turned off, the supply of GroP (the glue) dropped by about 36%.

The Analogy: Imagine the factory has a conveyor belt that brings in the glue (GroP). When the internal power plant is working, the conveyor belt runs fast, and there is plenty of glue for the Velcro. When the power plant is shut down and the factory switches to external fuel, the conveyor belt slows down or jams. Suddenly, there isn't enough glue to make the Velcro, so the factory stops making it to save the little glue it has for other essential tasks.

The Consequence: A New Weakness

When the bacteria stops making Velcro (LTA), it doesn't collapse immediately. It has a backup plan: it starts making more Wall Teichoic Acid (WTA). Think of WTA as a different type of tape that the bacteria uses to patch up the holes left by the missing Velcro.

This creates a new, interesting weakness:

• The bacteria is now dependent on WTA to survive because it has no Velcro.
• If you hit it with a drug that stops Velcro production (the FASII inhibitor) AND a second drug that stops the Wall Tape (WTA) production, the bacteria has no defenses left. It collapses.

The "Double-Whammy" Strategy

The study suggests a new way to fight these bacteria, called Bitherapy (using two drugs at once).

1. Drug A: Turns off the internal power plant. This forces the bacteria to stop making Velcro (LTA) and rely on Wall Tape (WTA).
2. Drug B: Attacks the Wall Tape (WTA).

Individually, these drugs might not kill the bacteria (it can survive without Velcro if it has Tape, and it can survive without Tape if it has Velcro). But together, they leave the bacteria with zero protection, causing it to die.

Summary

• The Problem: Bacteria can survive antibiotic attacks by switching to external fuel, but this switch accidentally turns off the production of a vital surface structure (LTA).
• The Cause: The switch causes a shortage of a specific "glue" molecule (GroP), forcing the bacteria to prioritize other lipids over LTA.
• The Solution: By combining a drug that triggers this switch with a drug that attacks the bacteria's backup defense (WTA), we can create a "double-whammy" that kills the bacteria effectively.

This research opens the door to smarter, more effective treatments for stubborn bacterial infections by exploiting the bacteria's own survival tricks against them.

Technical Summary

1. Problem Statement

• Metabolic Competition: In Staphylococcus aureus, the phospholipid phosphatidylglycerol (PG) serves as a common precursor for four distinct lipid products: Lipoteichoic Acid (LTA), Cardiolipin (CL), Lysyl-PG, and lipoproteins. The regulatory mechanisms determining how the cell directs metabolic flux toward LTA versus these other products remain unclear.
• LTA Importance: LTA is a critical cell envelope component essential for cell division, envelope homeostasis, and virulence. It comprises a glycerophosphate (GroP) polymer anchored to the membrane.
• FASII Bypass: S. aureus can survive the inhibition of its Type II Fatty Acid Synthesis (FASII) pathway (the target of certain antibiotics) by utilizing exogenous fatty acids (FAs) from the environment. This "FASII bypass" (FASIIbypass) allows bacterial growth but induces profound metabolic and proteomic changes. The study aims to determine how FASII activity influences LTA production and whether FASII inhibition creates a vulnerability that can be exploited therapeutically.

2. Methodology

The researchers employed a multidisciplinary approach combining genetics, lipidomics, metabolomics, and microbiology:

• Strains and Conditions: Used S. aureus USA300 (JE2) and NCTC 8325 lineages, as well as Streptococcus agalactiae.
  • FASII Inhibition: Achieved via chemical inhibitors (AFN-1252 targeting FabI; Platensimycin targeting FabF) or genetic deletion of fabD (FASII auxotroph).
  • FASIIbypass: Induced by growing bacteria in media supplemented with exogenous fatty acids (FA mixtures or single FAs like ai15).
  • Controls: Used a plsX deletion mutant (ΔplsX) to create a condition where membrane fatty acid composition mimics FASIIbypass but FASII activity remains intact, isolating the variable of FA composition vs. pathway activity.
• Phenotypic Analysis:
  • Transmission Electron Microscopy (TEM): To assess envelope thickness and morphology.
  • Immunoblotting: Used Clone 55 antibody to quantify LTA levels.
  • WTA Quantification: Alcian blue/silver nitrate staining to measure Wall Teichoic Acid (WTA).
  • Lipidomics: Normal Phase Liquid Chromatography (NPLC) coupled with Charged Aerosol Detection (CAD) and Mass Spectrometry (MS) to profile lipid classes (PG, CL, DG-DAG, etc.).
  • Metabolomics: LC-MS to quantify intracellular pools of ATP and Glycerol-3-phosphate (GroP).
• Genetic Manipulation: Overexpression of ltaS (LTA synthase), use of mspA mutants (affecting SpsB protease), and cls1cls2 double mutants (lacking cardiolipin synthases).
• Synergy Testing: Bitherapy assays combining anti-FASII drugs with Targocil (an anti-WTA inhibitor).

3. Key Contributions and Results

A. FASII Inhibition Drastically Depletes LTA

• Observation: When S. aureus adapts to FASII inhibition (FASIIbypass), LTA levels drop significantly (>10-fold reduction) compared to non-treated controls. This was confirmed using different inhibitors, genetic mutants (fabD), and across different S. aureus lineages.
• Conservation: The phenomenon was also observed in Streptococcus agalactiae when FASII was repressed by exogenous fatty acids, suggesting a conserved regulatory mechanism in Gram-positive pathogens.
• Exclusion of LtaS Limitation: Overexpression of ltaS (the enzyme synthesizing the LTA polymer) failed to restore LTA levels during FASIIbypass. Similarly, manipulating the SpsB protease (which processes LtaS) did not rescue LTA production. This indicates the bottleneck is upstream of the synthase enzyme.

B. Membrane Fatty Acid Composition is Not the Cause

• Hypothesis: It was initially suspected that the specific fatty acid composition of the membrane (which changes during FASIIbypass) might prevent proper LTA anchor formation.
• Experiment: Researchers compared FASIIbypass strains (using exogenous FAs) with ΔplsX mutants (which use FASII but incorporate exogenous FAs at the sn-1 position).
• Result: Both strains had nearly identical membrane fatty acid profiles. However, the ΔplsX mutant maintained normal LTA levels, while the FASIIbypass strain showed LTA depletion.
• Conclusion: The depletion is caused by the inhibition of FASII activity itself, not by the resulting membrane fatty acid composition.

C. The Mechanism: GroP Depletion

• Metabolite Analysis: The study identified that FASIIbypass leads to a ~36% reduction in intracellular Glycerol-3-phosphate (GroP) pools.
• ATP Levels: ATP pools were actually higher in FASIIbypass conditions (due to energy savings from not synthesizing FAs), ruling out energy depletion as the cause.
• The "Metabolic Fork": LTA synthesis is energetically expensive, requiring the transfer of GroP from ~25 PG molecules to build one polymer. When GroP is scarce (due to FASIIbypass), the cell prioritizes the synthesis of non-GroP consuming lipids (like Cardiolipin) over the costly LTA.
• Mechanism Proposal: The authors propose that FASIIbypass reverses the activity of the enzyme PlsX, leading to an accumulation of unstable intermediates (like lysophosphatidic acid) that undergo dephosphorylation, resulting in the futile loss of GroP.

D. Compensatory Mechanisms and Synthetic Lethality

• WTA Upregulation: In response to LTA depletion, S. aureus upregulates the production of Wall Teichoic Acid (WTA) by ~2-fold. WTA and LTA are known to cooperate in maintaining envelope integrity.
• Cardiolipin (CL): CL levels increase during FASIIbypass, but cls1cls2 mutants (lacking CL) can still adapt to FASII inhibition, indicating CL is not essential for survival in this context.
• Bitherapy Strategy: Because FASII inhibition depletes LTA and forces reliance on WTA, the researchers tested a combination of an anti-FASII drug (AFN-1252) and an anti-WTA drug (Targocil).
• Result: The combination treatment resulted in synergistic lethality, causing a >4-log reduction in bacterial survival, whereas single treatments were largely bacteriostatic or ineffective.

4. Significance

• Metabolic Insight: The study resolves the "metabolic fork dilemma" of PG utilization, demonstrating that the availability of the GroP precursor, controlled by FASII activity, dictates the flux toward LTA synthesis.
• Therapeutic Innovation: It identifies a novel vulnerability: S. aureus adapted to FASII inhibitors becomes dependent on WTA for survival due to LTA loss. This provides a strong rationale for antimicrobial bitherapy (combining anti-FASII and anti-WTA agents) to treat resistant S. aureus infections.
• Broad Applicability: The mechanism appears conserved in S. agalactiae, suggesting this metabolic checkpoint and the potential for combined targeting may apply to other Gram-positive pathogens.

In summary, the paper establishes that FASII activity is a critical checkpoint for LTA production via GroP availability. Inhibiting FASII starves the cell of GroP, depleting LTA and forcing a compensatory reliance on WTA, which can be exploited to kill the bacteria through dual-target therapy.